Review ArticleDesmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapiesHadfield, Matthew J.a; Helsing, Racquelb; Grant-Kels, Jane M.c,,dAuthor Information aDivision of Oncology, Department of Internal Medicine, University of Connecticut Health Center bSchool of Medicine, University of Connecticut cDepartment of Dermatology, University of Connecticut, Farmington, Connecticut dDepartment of Dermatology, University of Florida, Gainesville, Florida, USA Received 15 March 2020 Accepted 21 May 2020 Correspondence to Jane M. Grant-Kels, MD, UCONN Department of Dermatology, 21 South Road, Farmington, CT 06032, USATel: +1 800 535 6232; fax: +1 860 679 7692; e-mail: email@example.com Melanoma Research: October 2020 - Volume 30 - Issue 5 - p 429-432 doi: 10.1097/CMR.0000000000000679 Buy Metrics Abstract Desmoplastic melanoma (DM) is a rare and histopathologically as well as prognostically distinct subset of melanoma that arises in chronically sun-damaged skin. DM is typically and relatively indolent in nature with most cases not progressing to metastatic disease. DM has been managed with both radiation and surgical approaches. Medical options for the treatment of metastatic DM have traditionally been limited. Recent advances in immunotherapies have shown promising responses in DM ushering in a new class of treatment options. Additionally, with the advent of whole exome sequencing, the genetic make-up of DM has been further characterized creating new possibilities for future targeted therapies. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.